Implants for localized drug delivery and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10912933-B2
Application number	US-201515502742-A
Country	US
Kind code	B2
Filing date	Aug 18, 2015
Priority date	Aug 19, 2014
Publication date	Feb 9, 2021
Grant date	Feb 9, 2021

Abstract

Provided herein is an implant for delivering a hydrophobic active agent to a target tissue. The implant may include a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to a hydrophobic active agent, and a silicone tubing having a wall permeable to the active agent, wherein a first length of the silicone tubing is affixed to the first surface of the scaffold, wherein the two ends of the silicone tubing extend from the first surface, and wherein a path outlined by a second length of the tubing within the first length is circuitous. Also provided is a method of using the implant to locally deliver a hydrophobic active agent to a target tissue, and kits that find use in performing the present method.

First claim

What is claimed is:

1. An implant for delivering a hydrophobic active agent to a target tissue, the implant comprising:
a hydrophobic active agent;
a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to the hydrophobic active agent, the first surface of the scaffold spanning a first area; and
a silicone tubing defining a first end and a second end distal to the first end, the hydrophobic agent contained within a wall of the silicone tubing, on a surface of an inner wall of the silicone tubing, within an internal volume of the silicone tubing, or dissolved in a solution in the silicone tubing,
wherein the silicone tubing comprises a wall permeable to the hydrophobic active agent,
wherein a first length of the silicone tubing is affixed to the first surface of the scaffold,
wherein the first and second ends of the silicone tubing extend from the first surface,
wherein a path outlined by a second length of the tubing within the first length is circuitous on the first surface, and
wherein the first length of silicone tubing is fully contained within a second area which is less than the first area.

2. The implant according to claim 1 , wherein the silicone tubing is poly(dimethylsiloxane) tubing.

3. The implant according to claim 1 , wherein the scaffold defines first, second and third orthogonal dimensions, and wherein a total length of the silicone tubing is longer than the longest dimension of the first, second and third orthogonal dimensions.

4. The implant according to claim 1 , wherein the circuitous path comprises one or more switchbacks on the first surface of the scaffold.

5. The implant according to claim 1 , wherein the circuitous path comprises a spiral pattern.

6. The implant according to claim 1 , wherein the first length of the silicone tubing overlies 30% or more of the first surface of the scaffold.

7. The implant according to claim 1 , wherein an amount of liquid introduced into the implant from the first end of the silicone tubing under sufficient pressure is configured to advance through the tubing to reach the second end when a volume of liquid in the implant approximately equal to an internal volume of the silicone tubing between the first and second ends is displaced by the applied pressure.

8. The implant according to claim 1 , wherein the scaffold is substantially planar.

9. The implant according to claim 1 , wherein the scaffold is a polymeric scaffold.

10. The implant according to claim 1 , wherein the silicone tubing comprises an amount of the hydrophobic active agent sufficient to deliver a therapeutically effective amount of the hydrophobic active agent to the target tissue.

11. The implant according to claim 10 , wherein the silicone tubing comprises the hydrophobic active agent in an amount sufficient to achieve sustained delivery of the hydrophobic active agent into the target tissue.

12. The implant according to claim 1 , wherein the hydrophobic active agent is a steroid.

13. The implant according to claim 12 , wherein the steroid is cholesterol, estradiol, progesterone, testosterone, or derivatives or synthetic analogs thereof.

14. The implant according to claim 12 , wherein the steroid is an anti-estrogen.

15. The implant according to claim 14 , wherein the anti-estrogen is fulvestrant.

16. The implant according to claim 1 , wherein the implant comprises one of more suture tabs.

17. The implant according to claim 1 , wherein the implant further comprises one or more fill ports attached to the first and second ends of the silicone tubing.

18. The implant according to claim 17 , wherein the one or more fill ports comprise:
a first chamber in fluid communication at the fill port with the first end of the silicone tubing; and
a second chamber in fluid communication at the fill port with the second end of the silicone tubing.

19. The implant according to claim 17 , wherein the one or more fill ports comprise an imageable backing.

20. The implant according to claim 17 , wherein the one or more fill ports comprise one or more suture tabs.

21. The implant according to claim 1 , wherein the second area is 90% or less of the first area.

22. The implant according to claim 1 , wherein the second area is 80% or less of the first area.

23. The implant according to claim 1 , wherein the second area is 70% or less of the first area.

24. The implant according to claim 1 , wherein the second area is 60% or less of the first area.

25. The implant according to claim 1 , wherein the second area is 50% or less of the first area.

26. The implant according to claim 1 , wherein the second area is 40%-70% of the first area.

Assignees

• Univ California

Inventors

• Munster Pamela
• Kiriakis Jim
• Sbitany Hani
• Thomas Scott

Classifications

• A61M31/002 Primary

  Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50) · CPC title

• A61K31/56

  Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title

• A61K9/0092

  Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes · CPC title

• A61K9/0041

  Mammary glands, e.g. breasts, udder; Intramammary administration · CPC title

• A61K9/0024 Primary

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title